Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope, explains the outcomes from KEYNOTe 240 trial comparing pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC) patients.
What is KEYNOTE 240 Outcome in HCC
